Search company, investor...
Search

Predict your next investment

Venture Capital
curiecapital.nl

See what CB Insights has to offer

Investments

6

About Curie Capital

Curie Capital is a life science focused venture capital firm.

Curie Capital Headquarters Location

Johan Huizingalaan 763A

Amsterdam, 1066 VH,

Netherlands

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Curie Capital News

Cleara Biotech Raises $2.5M in Seed Financing

Sep 28, 2022

Cleara Biotech B.V. , an Utrecht, The Netherlands-based preclinical-stage biotechnology company spun out from University Medical Center Utrecht (UMCU), closed a $2.5m seed financing round earlier in the year. The round was led by Apollo Health Ventures, with participation from Curie Capital B.V., ROM Utrecht Region and Longevity Tech Fund. The proceeds will be used to progress the company’s compounds toward clinical development and further build its developmental pipeline and management team. Cleara focuses on developing therapies for treating different pathologies of “scarred cellular” senescence, including late-stage cancer and chronic diseases. The company has optimized two lead developmental candidates, CL04177 and CL04183, that can eliminate scarred cancer cells found in several late-stage cancers and chronic diseases in humans. It is aiming to develop precision medicine tools that treat specific diseases with clear niche-directed, anti-senescent lead candidates, accompanied with associated biomarkers, around its FOXO4-based D-amino acid peptides and pipeline against subtypes of senescence. Designed and optimized based on an extensive (3D) structural, molecular and cellular understanding of cell scarring’s mechanism of action and how FOXO4 restrains this particular form of the cell guardian p53, both lead compounds potently counter viability of scarred cancer cells in 2D culture and 3D organoids, as well as reduce the metastatic burden and infiltration in mouse in vivo models for metastatic colon cancer and triple-negative breast cancer. Furthermore, they show favorable pharmacokinetics and tissue distribution in mice, with an MTD that is well above their efficacious dose. Cleara has also appointed Dr. Angelos Stergiou, New York-based SELLAS Life Sciences’ President and Chief Executive Officer, as its Board of Directors Chairman. Dr. Stergiou is a leader in the biotechnology industry with more than 20 years of experience in immuno-oncology, drug development and health economics, as well as deep expertise in finance and corporate governance. Dr. Peter de Keizer is the Managing Director and Scientific Founder of the company. FinSMEs

Curie Capital Investments

6 Investments

Curie Capital has made 6 investments. Their latest investment was in Cleara Biotech as part of their Seed VC - II on September 9, 2022.

CBI Logo

Curie Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/28/2022

Seed VC - II

Cleara Biotech

$2.5M

Yes

4

2/22/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

12/13/2021

Series A - II

Subscribe to see more

Subscribe to see more

10

11/24/2020

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

7/14/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/28/2022

2/22/2022

12/13/2021

11/24/2020

7/14/2020

Round

Seed VC - II

Series A

Series A - II

Seed VC

Series A

Company

Cleara Biotech

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$2.5M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

10

10

Curie Capital Team

1 Team Member

Curie Capital has 1 team member, including current Managing Partner, Mariette van der Velden-Roesink.

Name

Work History

Title

Status

Mariette van der Velden-Roesink

BOM Brabant Ventures

Managing Partner

Current

Name

Mariette van der Velden-Roesink

Work History

BOM Brabant Ventures

Title

Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.